UltraClear is one of the fastest-rising aesthetic treatments of 2026, which means we have reached the exact moment when the machine name starts becoming more famous than anything I could tell you from the treatment desk.
RealSelf reported an 85% jump in UltraClear Laser interest in Q1 2026 as energy-based treatments gained ground. The appeal is obvious. UltraClear uses a 2910 nm erbium-doped fluoride-glass fiber laser and is marketed around precise water absorption, less collateral heat, customizable depth, lower discomfort, and recovery that can be substantially lighter than traditional aggressive resurfacing.
There is real published clinical evidence behind the platform. There is also a vocabulary problem: “UltraClear” can now mean a superficial treatment aimed at the stratum corneum, a moderate fractional resurfacing treatment, deeper dermal ablation, combined superficial/deep passes, full ablation, or laser-enabled tissue coring.
Those are not one procedure at seven intensities of optimism.
The first question is not “Is UltraClear good?”
The useful question is: Which UltraClear mode, at what depth and coverage, for which problem, on which skin?
The manufacturer currently describes seven modules. Superficial 3DMIRACL/Clear treatments target the uppermost skin layers for complexion and early photodamage. Clear+ moves into the epidermis. Ultra targets the dermis for wrinkles, texture and scars. UltraClear combines superficial and deeper effects. Laser-Coring is a different level of intervention intended to remove microscopic tissue cores. Full ablation and surgical functions go further again.
This is why asking someone online how much downtime “UltraClear” caused can be nearly meaningless without the protocol. One person may have had a superficial 10-micron treatment. Another may have received multipass fractional ablation deep enough to produce crusting for a week. Same brand. Completely different Thursday.
“Cold fiber laser” is engineering language, not a promise that nothing is injured
UltraClear is marketed as a “cold fiber laser.” That does not mean the treatment is nonthermal, nonablative, or incapable of producing a wound. The platform uses a 2910 nm wavelength with strong water absorption to ablate tissue with a relatively controlled surrounding zone of coagulation.
The goal is precision: remove or disrupt the intended microscopic tissue while limiting unnecessary thermal spread. Less collateral heat can matter for pain, healing, inflammation, and pigment risk. But ablation is still ablation. Published deeper-treatment studies report pinpoint bleeding, edema, erythema, and crusting because tissue was deliberately injured to trigger resurfacing and repair.
“Cold” should help you understand the technology. It should not talk you out of reading the recovery plan.
FDA-cleared is accurate. FDA-approved is not the same sentence.
The UltraClear Fractional Laser System has FDA 510(k) clearance as a Class II prescription laser system. Its current cleared indications include dermatologic procedures requiring coagulation, resurfacing and ablation of soft tissue, including skin resurfacing, wrinkles, rhytids, fine lines, textural irregularities, scar revision including acne scars, benign pigmented lesions, and other listed conditions. Ultra mode is cleared to produce fractional effects during resurfacing.
A 510(k) substantial-equivalence determination is not FDA premarket approval in the PMA sense. I have written a whole piece on why cleared, approved and registered are not interchangeable. UltraClear has a legitimate regulatory status. It does not need the status upgraded in conversation to sound more impressive.
Five published protocols, and the price of each one
Before any of the individual studies, look at what they say together. This is the whole argument of the piece in one rectangle.
| Study | Enrolled / completed | Protocol | Result reported | What recovery looked like |
|---|---|---|---|---|
| Low-fluence photoaging | 20, plus 3 more for histology | Two single-pass full-face treatments two months apart; ~10 micrometer depth, 25% coverage | Average 25.1% improvement in overall photoaging at three months, blinded image evaluation | Pain 1.9 / 10; mild-to-moderate erythema and edema |
| 2024 advanced photoaging | 22 enrolled, 15 completed | Three full-face and neck multipass treatments, six to eight weeks apart | Moderate-to-marked improvement at 90 days, blinded reviewers; high patient satisfaction | Pain 4.9 / 10; pinpoint hemorrhage, redness, swelling and crusting for five to seven days; two temporary hyperpigmentation |
| 2023 mild-versus-deep pilot | 37 enrolled, 35 completed | Up to four milder treatments with focal deeper treatment, against one deeper-settings treatment | Both groups averaged improvement on patient and investigator Global Aesthetic Improvement Scales | Mild to moderate, up to five days; no scarring or dyspigmentation in that study |
| 2024 acne scarring | 14 enrolled, 13 completed | Three treatments at six-to-eight-week intervals | Mean 47.3% improvement three months after the final treatment, blinded image evaluation | Trace-to-mild erythema, edema and pinpoint bleeding |
| 2024 Laser-Coring histology | 5 subjects, 15 microcores | Submental tissue coring | Channels averaging about 242 micrometers in diameter and roughly 980 micrometers in ablative depth, coagulation zone about 104 micrometers | Not a clinical outcome study — this one describes tissue, not faces |
The low-fluence study gives the superficial treatment a real evidence file
A prospective study enrolled 20 people with visible chronic facial photoaging. Participants received two full-face, single-pass treatments two months apart using a superficial 2910 nm mode with an estimated penetration depth of 10 micrometers and 25% coverage. Blinded image evaluation three months after treatment found an average 25.1% improvement in overall photoaging. Average pain was 1.9 out of 10.
Histology in three additional subjects showed superficial epidermal changes and dermal inflammation that returned toward baseline by two weeks. The clinical treatment produced mild-to-moderate erythema and edema.
That is a reasonable evidence base for saying a superficial 2910 nm treatment can improve mild photodamage with relatively low discomfort and limited recovery. It is not evidence that one lunchtime treatment creates deep resurfacing results.
The deeper photoaging study bought more change by asking more from the skin
A 2024 study enrolled 22 adults ages 44 to 80 with advanced facial photoaging and rhytides. Participants were scheduled for three full-face and neck multipass treatments six to eight weeks apart. Fifteen completed the study. At 90 days after the third treatment, blinded reviewers found moderate-to-marked improvement, and patient satisfaction was high.
Average pain was 4.9 out of 10—not horrifying, but not “I forgot anything happened.” Post-treatment responses included pinpoint hemorrhage, redness, swelling, and soft-tissue crusting lasting five to seven days. Two people developed temporary hyperpigmentation. No infection, scarring, or hypopigmentation was reported in study completers.
Seven of 22 enrolled participants did not complete the full study. Some withdrew or were lost to follow-up. Nearly a third of the people who signed up are not in the result, and nobody knows what their faces looked like — that belongs in the read even when the completers did well.
Here is the part I actually like: the results and the recovery move together. Deeper resurfacing produced more substantial change and a more substantial recovery. That is much more believable than a treatment promising CO₂-level remodeling with moisturizer-level inconvenience.
Same machine, two very different appointments
A 2023 pilot enrolled 37 people with photodamaged skin into two approaches: one group received up to four milder treatments with focal deeper treatment, while another received one treatment using deeper settings. Thirty-five completed follow-up. Both groups averaged “improvement” on patient and investigator Global Aesthetic Improvement Scales. Skin responses were generally mild to moderate and lasted up to five days, with no scarring or dyspigmentation reported in that study.
This is the study that makes the brand name almost beside the point. One platform produced two different treatment strategies because the settings, number of visits, and depth changed. “I am getting UltraClear” is therefore incomplete information in the same way “I am getting a laser” is incomplete information. The useful question is which version of the machine you are getting today, and what that version is expected to cost in recovery.
The acne-scar number is stronger than its decimal point
A 2024 study enrolled 14 people with rolling and/or boxcar acne scars; 13 completed three treatments at six-to-eight-week intervals. Blinded image evaluation reported a mean 47.3% improvement three months after the final treatment, with trace-to-mild erythema, edema, and pinpoint bleeding.
Take the finding seriously and the decimal place less so. A mean of 47.3% across thirteen completed faces is a tenth-of-a-percent claim resting on thirteen people; move one grader’s opinion on one face and that figure shifts by more than a decimal. Read it as a strong signal in a small prospective study, which is what it is, and not as a measurement.
The participants who completed the trial were Fitzpatrick II and III, so it does not by itself establish the same scar protocol and risk profile across every darker skin type. And acne scars are architectural: rolling, boxcar, ice-pick, tethered, and mixed scars do not all respond to the same device in the same way. A laser can be excellent and still not release a tethered scar that needs a different intervention.
Laser-Coring is a different level of procedure
Laser-Coring uses the same platform in a much more aggressive tissue-removal strategy. A 2024 histologic study treated five subjects in the submental area and examined 15 microcores. The channels averaged about 242 micrometers in diameter and roughly 980 micrometers in ablative depth, with a surrounding coagulation zone averaging about 104 micrometers.
Those are micron-level averages from five people. They describe what this laser did to that tissue with real precision, and they say nothing at all about how often it does that, in whom, or what the face looks like a year later. Histology can prove a channel exists. It cannot tell you whether your jawline will look seven years younger at twelve months.
If a consultation includes Laser-Coring, I would treat that as a separate procedure conversation with its own indication, depth, downtime, risk, and evidence—not as the premium package in a facial menu.
Skin of color needs more than the sentence “safe for all skin types”
The manufacturer markets UltraClear across all Fitzpatrick skin types and emphasizes the lower-thermal-injury profile. That is encouraging, particularly because post-inflammatory hyperpigmentation is a central concern in resurfacing darker skin.
But risk is never just the wavelength. Depth, density, passes, treatment interval, recent tanning, baseline pigment tendency, inflammatory history, pretreatment and aftercare, and provider experience all matter. The deeper 2024 photoaging study reported two temporary hyperpigmentation cases even in a controlled research context.
I would ask a provider for experience and outcome examples in your skin type using the proposed mode and settings. “The device can treat skin of color” and “this provider has a thoughtful protocol for my skin” are not interchangeable claims.
Make them put dates on it
“Minimal downtime” asks you to imagine that everyone has the same job, the same social calendar, the same pigment response and the same appetite for being visibly pink in a meeting. It is the single least informative phrase on any treatment menu, and the table above is why: the same machine produced five days of mild redness in one protocol and a week of crusting in another.
So make the recovery specific before you buy the result. Day one, day three, day five, day seven, for the exact protocol they are proposing. Makeup, and when. Peeling, crusting, swelling, pinpoint bleeding, occlusive ointment. Exercise and heat. When actives restart. And the finding that should make you pick up the phone rather than wait it out.
How UltraClear compares with CO₂, Er:YAG, and nonablative fractional lasers
I would not reduce this to “UltraClear is better.” Different lasers trade ablation depth, coagulation, thermal injury, pigment risk, recovery, treatment count, and magnitude of remodeling differently.
Fractional CO₂ remains a serious resurfacing tool with strong evidence and the ability to produce substantial remodeling, but it can carry more heat, recovery, and pigment risk. Er:YAG systems have high water absorption and are often valued for efficient ablation with less residual thermal damage than CO₂. Nonablative fractional lasers preserve the surface and generally trade lower downtime for a more gradual or smaller result and more sessions.
UltraClear’s 2910 nm fiber engineering adds another useful option rather than making the older modalities obsolete. The right answer is the one whose injury pattern matches the problem and the recovery you are willing to buy.
The cost question requires the whole protocol
UltraClear pricing varies materially by geography, provider, treatment area, mode, depth, number of passes, anesthesia, and whether the plan includes one aggressive session or a series of lighter ones. I would not pretend a single national average tells you much.
Price the plan instead: total induction series, realistic maintenance, prescribed skincare, medication if applicable, time away from work or social obligations, travel if needed, and the cost of managing an unexpected pigment issue or delayed recovery.
The manufacturer suggests superficial 3DMIRACL may be performed as a series of three to four treatments per year. Published deeper studies used protocols such as two or three sessions spaced by weeks to months. A $900 appointment and a three-treatment plan are not the same purchase even if the consultation only says “UltraClear.”
The consultation questions I would actually ask
- Which exact UltraClear module or combination are you recommending?
- What problem are we treating: pigment, photodamage, texture, wrinkles, acne scars, laxity, or something else?
- What depth, coverage, number of passes, and treatment count do you expect?
- What does day three usually look like with this exact protocol?
- What published evidence best resembles this mode, indication, and my skin type?
- How often have you used this protocol in skin like mine?
- What is the plan if I develop prolonged erythema or post-inflammatory hyperpigmentation?
- What result would make you say we should stop rather than simply add another treatment?
The device name should make the conversation more precise, not end it.
The Verdict
Promising platform. Real evidence. Absolutely not one treatment.
UltraClear has more going for it than novelty. It has FDA 510(k) clearance, several prospective human studies, a technically interesting wavelength and fiber-delivery system, favorable pain and recovery data at superficial settings, and evidence of meaningful improvement with deeper resurfacing protocols.
The vice is letting the brand name erase the dose. “Cold fiber” does not mean no injury. “Minimal downtime” does not describe every module. “Safe for all skin types” does not remove the need for pigment-aware settings and provider experience. Laser-Coring does not inherit every result from superficial 3DMIRACL, and 3DMIRACL does not inherit the remodeling magnitude of a deep multipass treatment.
I would put UltraClear on a serious consultation shortlist. Then I would ignore the machine name long enough to ask what, exactly, they plan to do with it to my skin. That is where the verdict lives.
Sources worth opening
- RealSelf: Q1 2026 aesthetic search trends; UltraClear +85%
- FDA 510(k) K233803: UltraClear Fractional Laser System indications and Class II clearance
- Low-fluence 2910 nm fiber-laser study for photodamage
- 2024 full-face and neck resurfacing study for advanced photoaging
- Clinical evaluation of mild vs deeper 2910 nm resurfacing protocols
- 2024 2910 nm fiber-laser study for acne scarring
- 2024 histologic analysis of UltraClear laser-enabled tissue coring
- UltraClear current patient treatment levels and downtime descriptions
Evidence note: UltraClear is a configurable prescription laser platform with materially different modules, depths, densities, passes, and indications. Outcomes and downtime from one published protocol should not be represented as the expected result of every UltraClear treatment. Percentages reported here are reproduced at the precision the published studies used; on samples of thirteen to twenty completers, that precision outruns what the sample can carry. FDA 510(k) clearance is not the same regulatory pathway as premarket approval.